Oncolytics Biotech Inc T.ONC

Pfizer turns over Bravencio to Merck.

[askretka]

https://endpts.com/merck-kgaa-takes-back-control-of-pd-l1-cancer-drug-as-pfizer-alliance-ends/
-----------------------------------------
Merck  vs Roche now?

[Noteable]

Along with Pfizer wanting to avoid potential antitrust issues on the acquisition of Seagen, by divesting in Bavencio (avelumab),  Pfizer is developing its own PD-1 immune checkpoint inhibitor - sasanlimab, which can be administered subqutaneously (subQ). Roche's (atezolizumab)Tecentriq  and Merck's (pembrolizumab) Keytruda have also developed their own subQ immune checkpoint

[Noteable]

GSK's PD-1 immune checkpoint inhibitor Jemperli could also become part of the group looking to combine with ONCY's pelareorep. https://www.fiercepharma.com/pharma/new-pd-1-showdown-gsks-jemperli-lost-chance-winning-streak-over-mercks-keytruda

[Noteable]

ONCY's Phase 2 GOBLET clinical study includes a cohort involving pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients in which GSK's PD-1 checkpoint inhibitor Jemperli and Merck's Keytruda are currently competing to gain prominence, as described in the previous post's attached link. https://www